Document is current

Article History

Received: 3 July 2018

Accepted: 27 August 2018

First Online: 5 October 2018

Ethics approval and consent to participate

: The UPLIFT® study was performed in accordance with the provisions of the Declaration of Helsinki (1996 version), in accordance with the International Conference on Harmonization Tripartite Guideline for Good Clinical Practice, and in accordance with applicable regulatory requirements and Boehringer Ingelheim Standard Operating Procedures. All patients provided written informed consent. This article does not report individual patient data; all data presented here is anonymized. The clinical trial protocol (dated 12 February 2002) and the informed consent and patient information forms were reviewed and received approval/favorable opinion from a constituted local Institutional Review Board or an Independent Ethics Committee at each center prior to the start of the study.

: DPT has been an advisory board member and speaker for Boehringer Ingelheim, AstraZeneca and Sunovion; and a consultant for Mylan and Theravance/Innovative Pharmaceuticals. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, ROVI, Grifols and Novartis; and consulting fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Gebro Pharma, CSL Behring, Novartis and Grifols. BRC has received consulting fees from Almirall, AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline; lecture fees from Almirall, AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline; and grant support from Boehringer Ingelheim, Forest Laboratories and GlaxoSmithKline. NM and AM are employees of Boehringer Ingelheim. DMGH has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Pfizer and Novartis. AA received grants or fees from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline and Novartis.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.